

# Dementia Curriculum for Health Care Professionals

## Module 8: References

### Medical Treatments of Dementia



## Module 8 References

- Aarsland, D. (2016). Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. *Parkinsonism and Related Disorders*, 22, S144–S148.
- Aarsland, D., Ballard, C., Rongve, A., Broadstock, M., & Svenningsson, P. (2012). Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. *Current Neurology and Neuroscience Reports*, 12, 492–501.
- Aarsland D., Ballard C., Walker Z., Bostrom F., Alves G., Kossakowski K., ...& Londos E. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. *Lancet Neurol*. 2009;8(7):613-618. doi:10.1016/S1474-4422(09)70146-2.
- Aging Brain Care, (2012). *Anticholinergic Cognitive Burden Scale: 2012 update*. Retrieved from <https://www.uea.ac.uk/documents/3306616/10940915/Anticholinergics/088bb9e6-3ee2-4b75-b8ce-b2d59dc538c2>
- Ahmed, A. I. A., van der Marck, M. A., van den Elsen, G. A. H., & Olde Rikkert, M. G. M. (2015). Cannabinoids in late-onset Alzheimer's disease. *Clinical Pharmacology & Therapeutics*, 97(6), 597–606.
- Alquézar, C., Esteras, N., de la Encarnación, A., & Martín-Requero, Á. (2013). Therapeutic approaches for the treatment of frontotemporal lobar degeneration. *Current Topics in Pharmacology*, 17(1), 85–101.
- American Geriatrics Society. (2015). *American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults*. Retrieved from <http://geriatricscareonline.org/ProductAbstract/american-geriatrics-society-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults/CL001>
- Arai, H., Sumitomo, K., Sakata, Y., Daidoji, K., Takase, T., & Toyoda, T. (2016). Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Interim results from the long-term, large-scale J-GOLD study in Japan. *Psychogeriatrics*, 16, 107–115.
- Atri, A., Molinuevo, J. L., Lemming, O., Wirth, Y., Pulte, I., & Wilkinson, D. (2013). Memantine in patients with Alzheimer's disease receiving donepezil: New analyses of efficacy and safety for combination therapy. *Alzheimer's Research & Therapy*, 5, 6.
- Atti, A. R., Gozzi, B. F., Zuliani, G., Bernabei, V., Scudellari, P., Berardi, D., ... & Menchetti, M. (2013). A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia. *International Psychogeriatrics*, 26(1), 19–37.
- Aurora, R. N., Zak, R. S., Maganti, R. K., Auerbach, S. H., Casey, K. R., Chowdhuri, S., ... & Morgenthaler, T. I. (2010). Best practice guide for the treatment of REM Sleep Behavior Disorder (RBD). *Journal of Clinical Sleep Medicine*, 6(1), 85–95.

- Averbeck, M. A., Altaweel, W., Manu-Marin, A., & Madersbacher, H. (2015). Management of LUTS in patients with dementia and associated disorders. *Neurourology and Urodynamics*. Advance online publication. doi: 10.1002/nau.22928
- Ballard, C., Aarsland, D., Francis, P., & Corbett, A. (2013). Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: Pathophysiology, clinical features, and pharmacological management. *Drugs and Aging*, 30, 603–611.
- Ballard, C., Kahn, Z., & Corbett, A. (2011). Treatment of dementia with Lewy bodies and Parkinson's disease dementia. *Drugs and Aging*, 28(10), 769–777.
- Banerjee, S., Hellier, J., Dewey, M., Romeo, R., Ballard, C., Baldwin, R., ... & Burns, A. (2011). Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomized, multicenter, double-blind, placebo-controlled trial. *Lancet*, 378(9789), 403–411.
- Berman, K., Brodaty, H., Withall, A., & Seeher, K. (2012). Pharmacologic treatment of apathy in dementia. *American Journal of Geriatric Psychiatry*, 20(2), 104–122.
- Birks, J., McGuinness, B., & Craig, D. (2013). Rivastigmine for vascular cognitive impairment. *Cochrane Database of Systematic Reviews*, 2013(5), CD004744. doi: 10.1002/14651858.CD004744.pub3
- Birks, J. S., Chong, L. Y., Grimley Evans, J., & Tsolaki, M. (2015). Rivastigmine for Alzheimer's disease. *Cochrane Database of Systematic Reviews*, 2015(9), CD001191. doi: 10.1002/14651858.CD001191.pub4
- Bishara, D., & Harwood, D. (2014). Safe prescribing of physical health medication in patients with dementia. *International Journal of Geriatric Psychiatry*, 29, 1230–1241.
- Borisovskaya, A., Pascualy, M., & Borson, S. (2014). Cognitive and neuropsychiatric impairments in Alzheimer's disease: Current treatment strategies. *Current Psychiatry Reports*, 16, 470.
- Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., ... & Miller, B. L. (2013). Memantine in frontotemporal lobar degeneration: A multicenter, randomized, double-blind, placebo-controlled trial. *Lancet Neurology*, 12(2), 149–156.
- Brown, R., Howard, R., Candy, B., & Sampson, E. I. (2015). Opioids for agitation in dementia. *Cochrane Database of Systematic Reviews*, 2015(5), CD009705. doi: 10.1002/14651858.CD009705.pub2
- Brunetti, V., Losurdo, A., Testani, E., Lapenta, L., Mariotti, P., Marra, C., Rossini P. M., & Della Marca, G. (2014). Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. *Current Alzheimer Research*, 11, 267–273.
- Burns, A., Perry, E., Holmes, C., Francis, P., Morris, J., Howes, M-J. R., ... & Ballard, C. (2011). A double-blind placebo-controlled randomized trial of *Melissa officinalis* oil and donepezil for the treatment of agitation in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, 31, 158–164.

Caccamo, A., Fisher, A., & LaFerla, F.M. (2009). M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. *Current Alzheimer's Research*, 6(2), 112-117.

Campos, C., Rocha, N. B. F., Vieira, R. T., Rocha, S. A., Telles-Correia, D., Paes, F., ... & Caixeta, L. (2016). Treatment of cognitive deficits in Alzheimer's disease: A psychopharmacological review. *Psiquiatria Danubina*, 28(1), 2-13.

Canevelli, M., Adali, N., Kelaiditi, E., Cantet, C., Ousset, P-J., Cesari, M., & the ICTUS/DSA Group. (2014). Effects of *Gingko biloba* supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study. *Phytomedicine*, 21, 888-892.

Centers for Medicare and Medicaid Services (CMS), Center for Clinical Standards and Quality, Survey and Certification Group. (2013). *Advanced copy: Dementia care in nursing homes: Clarification to Appendix P State Operations Manual (SOM) and Appendix PP in the SOM for F309-quality of care and F329-unnecessary drugs*. [Memorandum]. Baltimore, MD: Department of Health and Human Services. Retrieved from <https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and-Regions-Items/Survey-and-Cert-Letter-13-35.html>

Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sabreira, E. T., Bergamaschi, M. M., ... & Crippa, J. A. S. (2014). Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. *Journal of Psychopharmacology*, 28(11), 1088-1092.

Chen, Y. D., Zhang J., Wang Y., Yuan, J. L., & Hu, W.L. (2016). Efficacy of cholinesterase inhibitors in vascular dementia: An updated meta-analysis. *European Neurology*, 75(3-4), 132-141.

Clodomiro, A., Gareri, P., Puccio, G., Frangipane, F., Lacava, R., Castagna, A., ... & Bruni, A. C. (2013). Somatic comorbidities and Alzheimer's disease treatment. *Neurological Sciences*, 34, 1581-1589.

Connolly, B., & Fox, S. H. (2014). Treatment of cognitive, psychiatric and affective disorders associated with Parkinson's disease. *Neurotherapeutics*, 11, 78-91.

Cooper, C., Mukadam, N., Katona, C., Lyketsos, C. G., Blazer, D., Ames, D., ... & Livingston, G. (2013). Systematic review of the effectiveness of pharmacologic interventions to improve quality of life and well-being in people with dementia. *American Journal of Geriatric Psychiatry*, 21(2), 173-183.

Cummings, J., Lai, T-J., Hemrungronj, S., Mohandas, E., Kim, S. Y., Nair, G., & Dash, A. (2016). Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer's disease and dementia with Lewy bodies. *CNS Neuroscience & Therapeutics*, 22, 159-166.

D'Agata, E., Loeb, M. B. & Mitchell, S. L. (2013). Challenges assessing nursing home residents with advanced dementia for suspected urinary tract infections. *Journal of the American Geriatric Society*, 61(1), 62–66.

Dominguez, E., Chin, T-Y., Chen, C-P., & Wu, T-Y. (2011). Management of moderate to severe Alzheimer's disease: Focus on memantine. *Taiwanese Journal of Obstetrics & Gynecology*, 50, 415–423.

Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., ... & Cummings, J. L. (2001). Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, 56(9), 1154–1166.

Dubois, B., Tolosa, E., Katzschlager, R., Emre, M., Lees., A. J., Schumann, G., ... & Moline, M. L. (2012). Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study. *Movement Disorders*, 27(10), 1230–1238.

Emre, M., Ford, P. J., Bilgic, B., & Uç, E. Y. (2014). Cognitive impairment and dementia in Parkinson's disease: Practical issues and management. *Movement Disorders*, 29(5), 663–672.

Farrimond, L. E., Roberts, E., & McShane, R. (2012). Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: A systematic review. *BMJ Open*, 2, e000917.

Freund-Levi, Y., Bloniecki, V., Auestad, B., Tysen Bäckström, A. C., Lärksäter, M., & Aarsland, D. (2014). Galantamine versus risperidone for agitation in people with dementia: A randomized, twelve-week, single-center study. *Dementia and Geriatric Cognitive Disorders*, 38, 234–244.

Freund-Levi, Y., Jedenius, E., Tysen- Bäckström, A. C., Lärksäter, M., Wahlund, L-O., & Eriksson, M. (2014). Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: An open randomized trial. *American Journal of Geriatric Psychiatry*, 22(4), 341–348.

Goldman, J. G., & Holden, S. (2014). Treatment of psychosis and dementia in Parkinson's disease. *Current Treatment Options in Neurology*, 16, 281.

Gomperts, S. N. (2016) Lewy body dementias: Dementia with Lewy bodies and Parkinson disease dementia. *Continuum (Minneapolis Minnesota)*, 22(2), 435–463.

Greenblatt, H. K., & Greenblatt, D. J. (2016). Use of antipsychotics for the treatment of behavioral symptoms of dementia. *The Journal of Clinical Pharmacology*, 11(1), 1–10.

Hager, K., Baseman, A. S., Nye, J. S., Brashear, H. R., Han, J., Sano, M. ... & Richards, H. M. (2014). Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. *Neuropsychiatric Disease and Treatment*, 4(10), 391–401.

Hee, J., Chae, J., & Miller, B. J. (2015) Beyond urinary tract infections (UTIs) and delirium: A systematic review of UTIs and neuropsychiatric disorders. *Journal of Psychiatric Practice*, 21(6), 402–411.

Heller, T. Scott, H.M, Janicki, M.P., & Pre-Summit Workgroup on Caregiving and Intellectual/ Developmental Disabilities. (2018). Caregiving, intellectual disability, and dementia: Report of the Summit Workgroup on Caregiving and Intellectual and Developmental Disabilities. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, in press.

Henderson, V. W., Ala, T., Sainani, K. L., Bernstein, A. L., Stephenson, B. S., Rosen, A. C., & Farlow, M. R. (2015). Raloxifene for women with Alzheimer disease. *Neurology*, 85, 1937–1944.

Herrmann, N., Lanctôt, K. L., & Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: The Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. *Alzheimer's Research & Therapy*, 5(Suppl 1), 55.

Hindle, J. V. (2013). The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient. *Journal of Neural Transmission*, 120, 649–653.

Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., ... & Phillips, P. (2012). Donepezil and memantine for moderate-to-severe Alzheimer's disease. *The New England Journal of Medicine*, 366(10), 893–903.

Howell, M. J., & Schenck, C. H. (2015). Rapid eye movement sleep behavior disorder and neurodegenerative disease. *Journal of the American Medical Association – Neurology*, 72(6), 707–712.

Howes, L. G. (2014). Cardiovascular effects of drugs used to treat Alzheimer's disease. *Drug Safety*, 37, 391–395.

Hughes, L. E., Rittman, T., Regenthal, R., Robbins, T. W., & Rowe, J. B. (2015). Improving response inhibition systems in frontotemporal dementia with citalopram. *Brain*, 138, 1961–1975.

Hunt, L. J., Covinsky, K. E., Yaffe, K., Stephens, C. E., Miao, Y., Boscardin, W. J., & Smith, A. K. (2015). Pain in community-dwelling older adults with dementia: Results from the National Health and Aging Trends Study. *Journal of the American Geriatrics Society*, 63(8), 103–1511.

Husebo, B. S., Achterberg, W., & Flo, E. (2016). Identifying and managing pain in people with Alzheimer's disease and other types of dementia: A systematic review. *CNS Drugs*, 30(6), 481–497.

Husebo, B. S., Ballard, C., Cohen-Mansfield, J., Seifert, R., & Aarsland, D. (2014). The response of agitated behavior to pain management in persons with dementia. *American Journal of Geriatric Psychiatry*, 22(7), 708–717.

Igeta, H., Suzuki, Y., Tajiri, M., & Someya, T. (2014). Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia. *Human Psychopharmacology and Clinical and Experimental*, 29, 292– 294.

Jones, H. E., Hoshi, A., Shenkin, S., & Mead, G. E. (2016). The effect of treatment with selective serotonin reuptake inhibitors in comparison to placebo in the progression of dementia: A systematic review and meta-analysis. *Age and Ageing*, 45, 448–456.

Kachru, N., Carnahan, R. M., Johnson, M. L., & Aparasu, R. R. (2015). Potentially inappropriate anticholinergic medication use in older adults with dementia. *Journal of the American Pharmacists Association*, 55(6), 603–612.

Kaye, E. D., Petrovic-Poljak, A., Verhoeff, N. P. L. G., & Freedman, M. (2010). Frontotemporal dementia and pharmacologic interventions. *Journal of Neuropsychiatry and Clinical Neuroscience*, 22(1), 19–29.

Kerchner, G. A., Tartaglia, M. C., & Boxer, A. L. (2011). Abhorring the vacuum: Use of Alzheimer's disease medications in frontotemporal dementia. *Expert Reviews in Neurotherapy*, 11(5), 709–717.

Kröger, E., Mouis, M., Wilchesky, M., Berkers, M., Carmichael, P-H., van Marum, R., ... & Laroche, M-L. (2015). Adverse drug reactions reported with cholinesterase inhibitors: An analysis of 16 years of individual case safety reports from VigiBase. *Annals of Pharmacotherapy*, 49(11), 1197–1206.

Lai E. C-C., Wong, M. B., Iwata, I., Zhang, Y., Hsieh, C-Y., Yang, Y-H. K., & Setoguchi, S. (2015). Risk of pneumonia in new users of cholinesterase inhibitors for dementia. *Journal of the American Geriatric Society*, 63, 869–876.

Langballe, E. M., Engdahl, B., Nordeng, H., Ballard, C., Aarsland, D. & Selbæk, G. (2014). Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: A population-based study. *American Journal of Geriatric Psychiatry*, 22, 321–331.

Larsson, V., Aarsland, D., Ballard, C., Minthon, L., & Londos, E. (2010). The effect of memantine on sleep behavior in dementia with Lewy bodies and Parkinson's disease dementia. *International Journal of Geriatric Psychiatry*, 25, 1030–1038.

Laver, K., Dyer, S., Whitehead, C., Clemson, L., & Crotty, M. (2016). Interventions to delay functional decline in people with dementia: A systematic review of systematic reviews. *BMJ Open*, 6, e010767. doi:10.1136/bmjopen-2015-010767.

Leonpacher, A. K., Peters, M. E., Drye, L. T., Makino, K. M., Newell, J. A., Devanand, D. P. ... & the CitAD Research Group. (2016). Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: Evidence from the CitAD study. *American Journal of Psychiatry*, 173(5), 473–480.

Lertxundi, U., Isla, A., Solinis, M. A., Domingo-Echaburu, S., Hernandez, R., Peral-Aguirregoitia, J., & Medrano, J. (2015). Anticholinergic burden in Parkinson's disease inpatients. *European Journal of Clinical Pharmacology*, 71, 1271–1277.

Li, Y., Hai, S., Zhou, Y., & Dong, B. R. (2015). Cholinesterase inhibitors for rarer dementias associated with neurological conditions. *Cochrane Database of Systematic Reviews*, 2015(3), CD009444. doi: 10.1002/14651858.CD009444.pub3

Libro, R., Giacoppo, S., Rajan, T. S., Bramanti, P., & Mazzone, E. (2016). Natural phytochemicals in the treatment and prevention of dementia: An overview. *Molecules*, 21(4), 518. doi:10.3390/molecules21040518.

Liu, C. S., Chau, S. A., Ruthirskuhan, M., Lanctôt, K. L., & Herrmann, N. (2015). Cannabinoids for the treatment of agitation and aggression in Alzheimer's disease. *CNS Drugs*, 29, 615–623.

Livingstone N., Hanratty J., McShane R., & Macdonald G. Pharmacological interventions for cognitive decline in people with Down syndrome. *Cochrane Database of Systematic Reviews* 2015, Issue 10. Art. No.: CD011546. DOI: 10.1002/14651858.CD011546.pub2

Madson, K. A., & Brown, S. (2016). Rivastigmine: Dementia with Lewy bodies. *Hospital Pharmacy*, 51(2), 129–131.

Manabe, Y., Ino, T., Yamanaka, K., & Kosaka, K. (2016). Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. *Psychogeriatrics*, 16, 202–208.

Massoud, F., Desmarais, J. E., & Gauthier, S. (2011). Switching cholinesterase inhibitors in older adults with dementia. *International Psychogeriatrics*, 23(3), 372–378.

Matsunaga, S., Kishi, T., Yasue, I., & Iwata, N. (2015). Cholinesterase inhibitors for Lewy body disorders: A meta-analysis. *International Journal of Neuropsychopharmacology*, 19(2), pyv086. doi: 10.1093/ijnp/pyv086

Matsuzono, K., Hishikawa, N., Ohta, Y., Yamashita, T., Deguchi, K., Nakano, Y., & Abe, K. (2015). Combination therapy of cholinesterase inhibitor (donepezil or galantamine) plus memantine in the Okayama Memantine Study. *Journal of Alzheimer's Disease*, 45(3), 771–780.

Maust, D. T., Kim, H. M., Seyfried, L. S., Chiang, C., Kavanagh, J., Schneider, L. S., & Kales, H. C. (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia. Number needed to harm. *Journal of the American Medical Association – Psychiatry*, 72(5), 438–445.

McCleery, J., Cohen, D. A., & Sharpley, A. L. (2014). Pharmacotherapies for sleep disturbances in Alzheimer's disease. *Cochrane Database of Systematic Reviews*, 2014(3), CD009178. doi: 10.1002/14651858.CD009178.pub2

McGuinness, B., O'Hare, J., Craig, D., Bullock, R., Malouf, R., & Passmore, P. (2013). Cochrane review on "Statins for the treatment of dementia." *International Journal of Geriatric Psychiatry*, 28, 119–126.

Moran J.A., Ruffin, M.S., Keller, S.M., Singh, B.K., & Janicki, M.P., (2013). The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. *Mayo Clinic Proceedings*, 88(8), 831-840.

Mori, E., Ikeda, M., Nagai, R., Matsuo, K., Nakagawa, M., & Kosaka, K. (2015). Long-term donepezil use for dementia with Lewy bodies: Results from an open-label extension of Phase III trial. *Alzheimer's Research & Therapy*, 7(1), 5. doi:10.1186/s13195-014-0081-2

Mossello, E., & Ballini, E. (2012). Management of patients with Alzheimer's disease: Pharmacological treatment and quality of life. *Therapeutic Advances in Chronic Disease*, 3(4), 183–193.

Nardell, M., & Tampi, R. R. (2014). Pharmacological treatments for frontotemporal dementias: A systematic review of randomized controlled trials. *American Journal of Alzheimer's Disease & Other Dementias*, 29(2), 123–132.

Nordström, P., Religa, D., Wimo, A., Winblad, B., & Eriksson, M. (2013). The use of cholinesterase inhibitors and the risk of myocardial infarction and death: A nationwide cohort study in subjects with Alzheimer's disease. *European Heart Journal*, 34, 2585–2591.



- O'Brien, J. T., & Burns, A. (2011). Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology. *Journal of Psychopharmacology*, 25(8), 997–1019.
- O'Regan, J., Lanctôt, K. L., Mazereeuw, G., & Herrmann, N. (2015). Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: A meta-analysis of randomized controlled trials. *Journal of Clinical Psychiatry*, 76(11), e1424–e1431.
- Ortman, J. M., Velkoff, V. A., & Hogan, H. (2014). An aging nation: The older population in the United States (Current Population Reports, P25-1140). Washington, DC: U.S. Census Bureau.
- Pagano, G., Rengo, G., Pasqualetti, G., Femminella, G. D., Monzani, F., Ferrara, N., & Tagliati, M. (2015). Cholinesterase inhibitors for Parkinson's disease: A systematic review and meta-analysis. *Journal of Neurology, Neurosurgery, and Psychiatry*, 86(7), 767–773.
- Pariente, A., Fourrier-Réglat, A., Ducruet, T., Farrington, P., Béland, S-G., Dartigues, J-F., ... & Moride, Y. (2012). Antipsychotic use and myocardial infarction in older patients with treated dementia. *Archives of Internal Medicine*, 172(9), 648–653.
- Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013). Memantine and cholinesterase inhibitors: Complementary mechanisms in the treatment of Alzheimer's disease. *Neurotoxicity Research*, 24, 358–369.
- Pasqualetti, G., Tognini, S., Calsolaro, V., Polini, A., & Monzani, F. (2015). Potential drug–drug interactions in Alzheimer patients with behavioral symptoms. *Clinical Interventions in Aging*, 10, 1457–1466.
- Pengo, V., Zurlo, A., Voci, A., Valentini, E., De Zaiacomo, F., Catarini, M., ... & Giantin, V. (2016). Advanced dementia: Opinions of physicians and nurses about antibiotic therapy, artificial hydration and nutrition in patients with different life expectancies. *Geriatrics and Gerontology International*. Advance online publication. doi: 10.1111/ggi.12746. June 23, 2016
- Prasher, V.P. (2004). Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. *International Journal of Geriatric Psychiatry*, 19(6), 509-515.
- Reeve, E., Bell, J. S., & Hilmer, S. N. (2015). Barriers to optimizing prescribing and deprescribing in older adults with dementia: a narrative review. *Current Clinical Pharmacology*, 10, 168–177.
- Reppas-Rindlisbacher, C. E., Fischer, H. D., Fung, K., Gill, S. S., Seitz, D., Tannenbaum, C., ... & Rochon, P. A. (2016). Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: The effect of multiple physicians. *Journal of the American Geriatric Society*, 64, 492–500.
- Reus, V. I., Fochtmann, L.J., Eyler, A. E., Hilty, D. M., Horvitz-Lennon, M., Jibson, M. D., ... & Yager, J. (2016). The American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. *American Journal of Psychiatry*, 173(5), 543–546.
- Rive, B., Gauthier, S., Costello, S., Marre, C., & François, C. (2013). Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease. *CNS Drugs*, 27(7), 573–582.

Rockwood, K., Mitnitski, A., Black, S. E., Richard, M., Defoy, I., & the VASPECT study investigators. (2013). Cognitive change in donepezil treated patients with vascular or mixed dementia. *Canadian Journal of Neurological Science*, 40, 564–571.

Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012). Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. *Cochrane Database of Systematic Reviews*, 2012(3), CD006504. doi: 10.1002/14651858.CD006504.pub2

Russ, T. C. (2014). Cholinesterase inhibitors should not be prescribed for mild cognitive impairment. *Evidence Based Medicine*, 19(3), 101.

Seitz, D. P., Gill, S. S., Herrmann, N., Brisbin, S., Rapoport, M. U., Rines, J., ... & Conn, D. K. (2013). Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: A systematic review. *International Psychogeriatrics*, 25(2), 185–203.

Sepehry, A. A., Lee, P. E., Hsiung, G. Y. R., Beattie, B. L., & Jacova, C. (2012). Effect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression. *Drugs and Aging*, 29, 793–806.

Sheffrin, M., Miao, Y., Boscardin, W. J., & Steinman, M. A. (2015). Weight loss associated with cholinesterase inhibitors in individuals with dementia in a national healthcare system. *Journal of the American Geriatric Society*, 63, 1512–1518.

Stevens, S., & Comella, C. L. (2013). Rapid eye movement sleep behavior disorder. In: R.F. Pfeiffer and I. Bodis-Wollner (Eds.), *Parkinson’s disease and nonmotor dysfunction*, Current Clinical Neurology. New York: Springer Science + Business Media. doi 10.1007/978-1-60761-429-6-18

Stinton, C., McKeith, I., Taylor, J-P., Lafortune, L., Mioshi, E., Mak, E., ... & O’Brien, J. T. (2015). Pharmacological management of Lewy body dementia: A systematic review and meta-analysis. *American Journal of Psychiatry*, 172, 731–742.

Ströhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., Hellweg, R., ... & Rieckmann, N. (2015). Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: A systematic review and meta-analysis of effects on cognition in randomized controlled trials. *American Journal of Geriatric Psychiatry*, 23, 12.

Stubendorff K., Larsson V., Ballard C., Minthon L., Aarsland D., Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. *BMJ Open*. 2014;4(7):e005158. doi:10.1136/bmjopen-2014-005158.

Sura, S. D., Carnahan, R. M., Chen, H. & Aparasu, R. R. (2015). Anticholinergic drugs and health-related quality of life in older adults with dementia. *Journal of the American Pharmacists Association*, 55(3), 282–287.

Trenkwalder, C., Chaudhuri, D. R., Martinez-Martin, P., Rascol, O., Ehret, R., Vališ, M., ... & the PANDA study group. (2015). Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): A double-blind, randomized, placebo-controlled trial. *The Lancet*, 14, 1161–1170.

Trotti, L. M., & Karroum, E. G. (2016). Melatonin for sleep disorders in patients with neurodegenerative diseases. *Current Neurologic and Neuroscience Reports*, 16(7), 63. doi:10.1007/s11910-016-0664-3

Uriri-Glover, J., McCarthy, M., & Cesarotti, E. (2012). Solving the puzzle of Alzheimer disease. *The Nurse Practitioner*, 9, 21–27.

Van der Maaden, T., Hendriks, S. A., de Vet, H. C. W., Zomerhuis, M. T., Smalbrugge, M., Jansma, E. P., ... & van der Steen, J. T. (2015). Antibiotic use and associated factors in patients with dementia: A systematic review. *Drugs and Aging*, 32, 43–56.

Van der Steen, J. T., Lane, P., Kowall, N. W., Knol, D. L., & Volicer, L. (2012). Antibiotics and mortality in patients with lower respiratory infection and advanced dementia. *Journal of the American Medical Directors Association*, 13, 156–161.

Wang, H-F., Yu, J-T., Tang, S-W., Jiang, T., Tan, C-C., Meng, X-F., ... & Tan, L. (2015). Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, 86, 135–143.

Wang, J., Yu, J-T., Wang, H-F., Meng, X-F., Wang, C., Tan, C-C., & Tan, L. (2015). Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: A systematic review and meta-analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, 86, 101–109.

Weintraub, D., Chiang, C., Kim, H. M., Wilkinson, J., Marras, C., Stanislawski, B., ... & Kales, H. C. (2016). Association of antipsychotic use with mortality risk in patients with Parkinson disease. *Journal of the American Medical Association- Neurology*, 73(5), 535–541.

Wesnes, K. A., Aarsland, D., Ballard, C., & Londos, E. (2014). Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. *International Journal of Geriatric Psychiatry*, 30(1), 46–54.

Wilkinson, D., Wirth, Y., & Goebel, C. (2014). Memantine in patients with moderate to severe Alzheimer's disease: Meta-analyses using realistic definitions of response. *Dementia and Geriatric Cognitive Disorders*, 37(1-2), 71–85.

Wood, L. D., Neumiller, J. J., Setter, S. M., & Dobbins, E. K. (2010). Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. *The American Journal of Geriatric Pharmacotherapy*, 8, 294–315.

Zdanys, K. F., & Steffens, D. C. (2015). Sleep disturbances in the elderly. *Psychiatric Clinics of North America*, 38, 723–741.

Zhai, Y., Yin, S., & Zhang, D. (2016). Association between antipsychotic drugs and mortality in older persons with Alzheimer's disease: A systematic review and meta-analysis. *Journal of Alzheimer's Disease*, 52, 631–639.

## Module 8 Additional Reading Material

Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: Advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An Update for 2015. An American Academy of Sleep Medicine Clinical Practice Guideline. *Journal of Clinical Sleep Medicine*, 11(10), 1199–1236.

Buckley, J. S., & Salpeter, S. R. (2015). A risk-benefit assessment of dementia medications: Systematic review of the evidence. *Drugs and Aging*, 32, 453–467.

Canevelli, M., Talarico, G., Tosto, G., Troili, F., Lenzi, G. L., & Bruno, L. (2013). Rivastigmine in the treatment of hypersexuality in Alzheimer disease. *Alzheimer Disease and Associated Disorders*, 27(3), 287–288.

Ferris, S. H., Schmitt, F. A., Saxton, J., Richardson, S., Mackell, J., Sun, Y., & Xu, Y. (2011). Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. *Alzheimer's Research & Therapy*, 3, 22. Retrieved from <http://alzres.com/content/3/3/22>.

Goldman, J. G., & Golden, S. (2014). Treatment of psychosis and dementia in Parkinson's disease. *Current Treatment Options in Neurology*, 16, 281.

Goodman R.A., Lochner K.A., Thambisetty M., Wingo T.S., Posner S.F., & Ling S.M. (2017). Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. *Alzheimers Dementia*, 13(1): 28-37. doi: 10.1016/j.jalz.2016.04.002. Epub 2016 May 10. PMID: 27172148

Grover, S., Somaiya, M., Kumar, S., & Avasthi, A. (2015). Psychiatric aspects of Parkinson's disease. *Journal of Neurosciences in Rural Practice*, 6(1), 65–76.

Jelic, V., & Winblad, B. (2016). Donepezil and nursing home placement – benefits and costs. *Nature Reviews Neurology*, 12, 11–13.

Koponen, M., Taipale, H., Tanskanen, A., Tolppanen, A-M., Tiihonen, J., Ahonen, R., & Hartikainen, S. (2015). Long-term use of antipsychotics among community-dwelling persons with Alzheimer's disease: A nationwide register-based study. *European Neuropsychopharmacology*, 25, 1706–1713.

Lachaine, J., Beauchemin, C., Crochard, A., & Bineau, S. (2013). The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: Analysis using the Régie de l'Assurance Maladie du Québec Database. *Canadian Journal of Psychiatry*, 58(4), 195–200.

Lee, C. W-S., Lin, C-L., Sung, F-C., Liang, J-A., & Kao, C-H. (2016). Antidepressant treatment and risk of dementia: A population-based, retrospective case-control study. *Journal of Clinical Psychiatry*, 77(1), 117–122.

Leong, C. (2014). Antidepressants for depression in patients with dementia: A review of the literature. *The Consultant Pharmacist*, 29(4), 254–263.

Levine, D. A., & Langa, K. M. (2011). Vascular cognitive impairment: disease mechanisms and therapeutic implications. *Neurotherapeutics*, 8, 361–373.

Livingstone, N., Hanratty, J., McShane, R., & Macdonald, G. (2015). Pharmacological interventions for cognitive decline in people with Down syndrome. *Cochrane Database of Systematic Reviews*, 2015(10), CD011546. doi: 10.1002/14641858.CD011546.pub2

Loy, C., & Schneider, L. (2009). Galantamine for Alzheimer's disease and mild cognitive impairment. *Cochrane Database of Systematic Reviews*, 2009(1), CD001747. doi: 10.1002/14651858.CD001747.pub3

Luijendijk, H. J., de Bruin, N. C., Hulshof, T. A., & Koolman, X. (2016). Terminal illness and the increased mortality risk of conventional antipsychotics in observed studies: A systematic review. *Pharmacoepidemiology and Drug Safety*, 25, 113–122.

Saleh, S., Kirk, A., Morgan, D. G., & Karunanayake, C. (2013). Less education predicts anticholinesterase discontinuation in dementia patients. *Canadian Journal of Neurologic Science*, 40, 684–690.

Shao, Z-Q. (2015). Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease. *International Journal of Clinical and Experimental Medicine*, 8(2), 2944–2948.

Shinagawa, S. (2015). Neuropsychiatric management of young-onset dementias. *Psychiatric Clinical of North America*, 38, 323–331.

Tan, L., Tan, L., Wang, H-F., Wang, J., Tan, C-C., Tan, M-S., ... & Yu, J-T. (2015). Efficacy and safety of atypical antipsychotic drug treatment for dementia: A systematic review and meta-analysis. *Alzheimer's Research & Therap*, 7, 20.

Waldemar, G., Gauthier, S., Jones, R., Wilkinson, D., Cummings, J., Lopez, O., ... & Mackell, J. (2011). Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. *International Journal of Geriatric Psychiatry*, 26, 150–157.

## Module 8 Resources

Anticholinergic Burden Scale:

[https://americandeliriumsociety.org/files/ACB\\_Handout\\_Version\\_03-09-10.pdf](https://americandeliriumsociety.org/files/ACB_Handout_Version_03-09-10.pdf)

Clinical trials finder:

<https://www.nia.nih.gov/alzheimers/clinical-trials>

<http://www.alz.org/trialmatch>

<https://clinicaltrials.gov>

[www.ResearchMatch.org/roar](http://www.ResearchMatch.org/roar)

American Psychiatric Association. Choosing wisely.

[www.psychiatry.org/psychiatrists/practice/quality-improvement/choosing-wisely](http://www.psychiatry.org/psychiatrists/practice/quality-improvement/choosing-wisely)

Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., ... & Cummings, J.L. (2001). Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, 56(9), 1154–1166.

Knopman, D.S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey-Bloom, J., Relkin, N., ...Stevens, J. C. (2001). Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, 56(9), 1143–1153.

<http://www.neurology.org/content/56/9/1143.full>.

O'Brien, J. T., & Burns, A. (2011). Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology. *Journal of Psychopharmacology*, 25(8), 997–1019.

Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001). Practice Parameter: Early detection of dementia: Mild Cognitive Impairment (An evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, 56, 1133–1142.

Rabins, P. V., Rovner, B. W., Rummans, T., Schneider, L. S., & Tariot, P. N. *Guideline watch (October 2014): Practice guideline for the treatment of patients with Alzheimer's disease and other dementia*. Arlington, VA: American Psychiatric Association, 2014.